Athersys

News

Athersys-Pfizer IBD phase 2 trial to wrap up by end of the year

Stem cell therapeutics developer Athersys’ (NASDAQ:ATHX) phase 2 clinical study investigating the treatment of inflammatory bowel disease with partner Pfizer (NYSE:PFE) is expected to complete patient enrollment by the end of 2012. Top-line results of the inflammatory bowel disease trial are likely to be available in early 2013, Athersys CEO Gil Van Bokkelen said in […]

News

Athersys awarded stem cell patent for graft-versus-host disease

Stem cell developer Athersys (NASDAQ:ATHX) has received a U.S patent that covers the use of nonembryonic, multipotent stem cells in the treatment of graft-versus-host disease. Graft-versus-host disease (GvHD) often occurs after a stem cell or bone marrow transplant in which the newly transplanted material attacks the transplant recipient’s body. The condition is often associated with […]

News

Athersys CEO: Stroke therapy could be one of biggest blockbusters ever

Gil Van Bokkelen, CEO of stem cell company Athersys (NASDAQ:ATHX), is typically one to speak in cautious and measured tones, but he made a brash statement in the company’s most recent quarterly earnings call. Van Bokkelen said Cleveland-based Athersys’ MultiStem stem cell therapy for ischemic stroke “could easily be one of the biggest blockbusters that […]

presented by
News

Stem cell company Athersys secures $9M in private stock sale

Stem cell developer Athersys (NASDAQ:ATHX) has secured $9 million in a private placement with an unidentified investor. Cleveland-based Athersys said it would issue about 4.3 million shares of common stock and an equal number of warrants to purchase common shares at a price of $2.07. The warrants are exercisable for five years, according to a […]

News

Athersys touts results of phase 1 blood diseases trial

Stem cell therapy developer Athersys (NASDAQ:ATHX) reported positive results from a phase 1 clinical trial in patients with leukemia and similar blood diseases. The trial showed that the company’s MultiStem technology may reduce the incidence and severity of graft-versus-host disease, according to a statement from Cleveland-based Athersys. Graft-versus-host disease (GvHD) often occurs after a stem […]

News

Stem cell company Athersys gets grant to study traumatic brain injury

Stem cell developer Athersys (NASDAQ:ATHX) has received $3.6 million in new grant funding, with one of the grants going toward studying its MultiStem technology for the treatment of traumatic brain injury. A $1.9 million grant to study traumatic brain injury (TBI) comes from the National Institute of Neurological Disorders and Stroke, according to a statement […]